Neurent Raises $74M to Commercialize Treatment for Nasal Condition

Why It Matters

The funding positions Neurent to scale a proven, minimally invasive therapy for a condition affecting 25 % of adults, potentially reshaping the rhinitis treatment landscape and generating sizable revenue streams.

Key Takeaways

• €62.5M Series C funding fuels global rollout
• FDA cleared Neuromark uses low‑power radiofrequency
• 55% symptom reduction shown in two‑year study
• Reimbursement codes secured with Cigna, UnitedHealthcare
• Chronic rhinitis impacts one in four adults globally

Pulse Analysis

Chronic rhinitis, affecting roughly one in four adults, remains a therapeutic blind spot despite its prevalence and impact on quality of life. Traditional pharmacologic options often provide incomplete relief and can carry side‑effects, prompting clinicians to seek device‑based alternatives. Neuromark’s low‑power radiofrequency technology creates precise lesions in the nasal mucosa, attenuating parasympathetic signaling that drives mucus overproduction. Clinical data show a 55 % drop in the Total Nasal Symptom Score, with improvements across congestion, rhinorrhea, sneezing and itching, positioning the device as a compelling non‑drug solution.

The €62.5 million Series C injection, led by MVM Partners and Sofinnova Partners, underscores growing investor confidence in med‑tech platforms that combine clear regulatory pathways with scalable reimbursement models. Prior FDA 510(k) clearances in 2021, 2022 and 2025 have de‑risked the product’s market entry, while the involvement of established life‑science backers such as EQT Life Sciences and Atlantic Bridge provides strategic guidance for global distribution. This capital will fund sales force expansion, manufacturing capacity, and next‑generation device refinements, accelerating Neuromark’s penetration beyond its current European stronghold into the U.S. and Asian markets.

Securing reimbursement codes from Cigna and UnitedHealthcare in late 2025 removed a critical barrier, allowing providers to bill the procedure without experimental designations. As payers recognize the cost‑saving potential of reducing chronic medication use and downstream complications, broader coverage is likely to follow, driving volume growth. For patients, wider access translates into faster symptom relief and fewer missed workdays, while health systems stand to benefit from lower overall treatment expenditures. The convergence of clinical efficacy, regulatory clearance, financing, and payer acceptance positions Neuromark to become a standard of care for chronic rhinitis.

Neurent raises $74M to commercialize treatment for nasal condition

By Nick Paul Taylor, Contributor · Published Feb. 12, 2026 · Neurent Medical CEO Brian Shields shows the company’s Neuromark device to treat chronic rhinitis. Courtesy of Neurent Medical

Dive Brief

• Neurent Medical has raised 62.5 million euros ($74 million) to commercialize a device that treats a common nasal condition.

• The Series C financing will enable Neurent to expand commercialization of a product that delivers radio‑frequency energy to treat chronic rhinitis symptoms such as nasal congestion.

• Neurent received Food and Drug Administration clearance for the latest version of the device, sold as Neuromark, last year.

Dive Insight

Neuromark delivers low‑power radiofrequency to create lesions that affect nasal nerves. By disrupting parasympathetic nerve signals, the lesions can reduce symptoms of allergic and non‑allergic rhinitis such as nasal congestion and runny nose.

In a two‑year study, Neurent reported a 55 % reduction in the mean reflective Total Nasal Symptom Score from baseline. The score assesses congestion, rhinorrhea, sneezing and itching. Neurent saw significant improvements in all four areas, as well as in post‑nasal drip and cough. Patients reported better quality of life after undergoing treatment.

Neuromark received 510(k) clearance in 2021. The FDA cleared updated versions of the device in 2022 and 2025.

Having received a reimbursement code at the start of 2024, Neurent secured expanded coverage for Neuromark last year. Cigna stopped classifying the procedure code as experimental and investigational in September 2025, increasing access to the device. UnitedHealthcare’s Medicare Advantage policy took the same action a month later.

With millions of patients gaining access to Neuromark, investors have backed Neurent’s plans to step up commercialization of the device. MVM Partners led the investment in the Irish med‑tech company and Sofinnova Partners was a significant participant in the round. Existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland also participated in the financing.

The investment reflects Neuromark’s potential to address a condition that affects millions of people and has limited effective treatment options. Neurent said one in four adults experiences chronic rhinitis, a condition that can be caused by overactive nerves that drive mucus production.